Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02964741 · ClinicalTrials.gov registry record · NA

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

A NA study, sponsored by University of Michigan.

Terminated
Registry status
NA
Development phase
44
Enrollment target

NCT02964741: Clinical Trial NA study, sponsored by University of Michigan.

NCT02964741 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02964741, a NA study, was terminated before completion, sponsored by University of Michigan.

TERMINATED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

This study investigates whether non-invasive brain stimulation, given for 20 minutes/once per day for ten days (M-F) can reduce migraine pain. Thirty patients will receive this treatment, while thirty will receive a "sham" procedure. Up to thirty healthy volunteers will be asked to undergo baseline assessments only (imaging, but no brain stimulation). Healthy volunteer data may be used from a prior study (NINDS-K23062946 project \[IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator\]).

Primary Outcome

Moderate to severe headache is defined by the pain over 3 in an Numeric Rating Scale (NRS) ranging from 0 to 10 between end of treatment and one month follow-up.

Interventions

  • DEVICE Sham Comparator
  • DEVICE Active Comparator

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2017-02-22
Est. Completion 2021-08-01
Phase NA
University of Michigan

1,327 total trials

Why NCT02964741 stopped before completion

NCT02964741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.

NCT02964741 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02964741 about?

NCT02964741 is a clinical study titled "Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)". This study investigates whether non-invasive brain stimulation, given for 20 minutes/once per day for ten days (M-F) can reduce migraine pain. Thirty patients will receive this treatment, while thirty will receive a "sham" procedure. Up to thirty healthy volunteers will be asked to undergo baseline ...

What is the current status of trial NCT02964741?

This trial is currently terminated. It is a NA study. The enrollment target is 44 participants. The study started on 2017-02-22. Estimated completion is 2021-08-01.

What interventions are being tested in trial NCT02964741?

The interventions under investigation include: Sham Comparator (DEVICE), Active Comparator (DEVICE).

Who is sponsoring clinical trial NCT02964741?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02964741's enrollment target sits among peer trials

44 1423rd of 2000 higher than 566 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02964741, the US trial registry maintained by the National Library of Medicine. NCT02964741 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.